Searching News Database: REVLIMID
HSMN NewsFeed - 6 Jan 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
HSMN NewsFeed - 18 Sep 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
HSMN NewsFeed - 5 Sep 2018
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
HSMN NewsFeed - 29 Jan 2013
Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer
Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer
HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
HSMN NewsFeed - 25 Aug 2009
Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
HSMN NewsFeed - 19 Feb 2008
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
Additional items found! 33
Members Archive contains
33 additional stories matching:
REVLIMID
(Password required)
REVLIMID
(Password required)